DLAT and autoimmune hepatitis: The biodistribution of ImmTOR nanoparticles to the liver and its multipronged effects on promoting a tolerogenic phenotype in antigen-presenting cells and T cells suggest that ImmTOR may be beneficial in the treatment of liver autoimmune diseases, either alone or combined with autoantigens, such as PDC-E2, to restore immune tolerance to autoantigens.